Company Filing History:
6 out of 245 
3 out of 672 
2 out of 15,488 
Years Active: 1998-2012
Title: The Innovative Journey of Keting Chu: Pioneering Cancer Therapies
Introduction
Keting Chu, an accomplished inventor based in Burlingame, California, has made significant strides in the field of oncology through his innovative work on B-cell malignancies. With a robust portfolio of 11 patents, Chu has positioned himself as a key figure in developing therapeutic methods that harness the power of antibodies to combat cancer.
Latest Patents
Keting Chu's latest groundbreaking patents focus on methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies. His innovative approaches detail the process of administering a therapeutically effective amount of these antibodies to patients in need. The antibodies in his patents are characterized by their agonist-free activity when interacting with normal human B cells and their antagonist effects on malignant cells. This dual action is pivotal, as it not only inhibits the proliferation and differentiation of cancerous cells but also preserves the functionality of healthy B cells. Such advancements have the potential to transform treatment options for patients suffering from B-cell malignancies.
Career Highlights
Throughout his illustrious career, Keting Chu has collaborated with leading companies such as Novartis Vaccines & Diagnostics and Chiron Corporation. His work in these organizations has been instrumental in the development of innovative therapeutic strategies that leverage the immune system in fighting cancer. Chu's dedication to his field has also led to numerous accolades, further establishing his reputation as a thought leader in cancer research.
Collaborations
In his pursuit of innovation, Keting Chu has worked alongside notable colleagues, including Lorianne K. Masuoka and David Pot. These collaborations have resulted in fruitful exchanges of ideas and strategies, propelling advancements in cancer therapies. The synergy created within such partnerships highlights the importance of teamwork in driving research forward.
Conclusion
Keting Chu's contributions to cancer therapy through his patented methodologies reflect his commitment to advancing medical science. As he continues to innovate and collaborate with fellow researchers, the impact of his work promises to enhance treatment options and improve patient outcomes in the fight against B-cell malignancies. Chu's journey is a testament to the possibilities that stem from dedication, creativity, and collaboration in the field of healthcare innovation.